Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06217120
PHASE2

Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

Sponsor: Montreal Heart Institute

View on ClinicalTrials.gov

Summary

This study will evaluate the impact of colchicine on the change in myocardial flow reserve (MFR), a marker for coronary microvascular dysfunction (CMD), compared to a matched placebo in patients with heart failure and ejection fraction above 40% (including patients with improved EF).

Official title: Reversing Microvascular Dysfunction in Heart Failure With Ejection Fraction > 40% Using Colchicine (The COL-Micro-HF Study)

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2026-11-06

Completion Date

2028-05

Last Updated

2026-11-10

Healthy Volunteers

No

Interventions

DRUG

Colchicine

Colchicine 0.6 mg once daily

DRUG

Placebo

Placebo once daily

Locations (1)

Centre de recherche du Centre hospitalier de l'Université de Montréal

Montreal, Quebec, Canada